Back to CRIS
Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
0 competitors in Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations
View Full LandscapeDrug Information
Target Indication
Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations
Clinical Trial
NCT02674750Last updated: 2/15/2026
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts